BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21861215)

  • 1. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.
    Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL
    Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
    Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
    Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zhu CB; Wang C; Chen LL; Ma GL; Zhang SC; Su L; Tian JJ; Gai ZT
    PLoS One; 2012; 7(9):e44648. PubMed ID: 22970277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
    J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
    Tsai MC; Yen YH; Chang KC; Hung CH; Chen CH; Lin MT; Hu TH
    BMC Cancer; 2019 Dec; 19(1):1169. PubMed ID: 31791275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
    Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
    Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.
    Lin ZX; Ruan DY; Li Y; Wu DH; Ma XK; Chen J; Chen ZH; Li X; Wang TT; Lin Q; Wen JY; Wu XY
    World J Gastroenterol; 2015 Oct; 21(38):10898-906. PubMed ID: 26478681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
    Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
    World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy.
    Wu SJ; Zhang ZZ; Cheng NS; Xiong XZ; Yang L
    Surg Oncol; 2019 Jun; 29():159-167. PubMed ID: 31196483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
    Johansen JS; Brasso K; Iversen P; Teisner B; Garnero P; Price PA; Christensen IJ
    Clin Cancer Res; 2007 Jun; 13(11):3244-9. PubMed ID: 17545529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment.
    Cho HJ; Kim SS; Ahn SJ; Park SY; Park JH; Kim JK; Wang HJ; Cheong JY; Cho SW
    Cytokine; 2015 Jun; 73(2):245-52. PubMed ID: 25797190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
    Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
    Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection.
    Yang HJ; Jiang JH; Liu QA; Zhou CM; Du YF; Wu T; Chen NZ; Xiang BD
    Tumour Biol; 2017 Jun; 39(6):1010428317707375. PubMed ID: 28639906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tissue polypeptide specific antigen as a noninvasive prognostic indicator for early recurrence of hepatocellular carcinoma after curative resection.
    Yao WJ; Wang ST; Chow NH; Chang TT; Lin PW; Tu DG
    Cancer; 2002 Jul; 95(1):112-8. PubMed ID: 12115324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
    Tarpgaard LS; Guren TK; Glimelius B; Christensen IJ; Pfeiffer P; Kure EH; Sorbye H; Ikdahl T; Yilmaz M; Johansen JS; Tveit KM
    PLoS One; 2014; 9(2):e87746. PubMed ID: 24498368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.